Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative Neoplasms

NCT06798805 · tracked via the Priya Life Science Italy tracker

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Phase

Observational

Started

2022-02-15

Last updated

2025-01-29

Condition(s) studied

Essential Thrombocythemia (ET)Myelofibrosis (MF)Polycythemia Vera (PV)

Study summary

In this study the aim is to investigate the pathogenetic role of extracellular vesicles and senescence in Myeloproliferative Neoplasms. In particular, the goal of this project is to identify possible EV-based biomarkers of senescence according to gender, which are disease-specific, biology-related, and predictive of short-term outcome in terms of Event-Free Survival and to define personalized targets for new therapeutic approaches.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Accepted

Inclusion criteria for patients: * age ≥ 18 years. * patients with WHO2017-defined diagnosis of Myeloproliferative Neoplasms. * patients at first diagnosis. * Informed consent signed. Exclusion criteria for patients: \- patients with concomitant second neoplasia Inclusion criteria for Healthy Donors: * age ≥ 18 years. * Informed consent signed. Exclusion criteria for Healthy Donors: \- Healthy Donors with neoplasia.

Primary outcome measure(s)

Plasma extracellular vesicle characterization — 2 years
Comparison of concentration (particles/mL), phenotype, and cargo between extracellular vesicles from patients and healthy donors.
Validation of extracellular vesicles as biomarker — 2 years
Correlation of extracellular vesicles' characterization data with markers of disease aggressiveness.

Trial sites (5)

Facility	City	Region
IRCCS Azienda Ospedaliero-Universitaria di Bologna	Bologna	Bologna
ASST Spedali Civili di Brescia	Brescia	BS
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori- IRST	Meldola	FC
Ospedale S.Maria delle Croci	Ravenna	RA
Arcispedale S. Maria Nuova - IRCCS	Reggio Emilia	RE

More IRCCS Azienda Ospedaliero-Universitaria di Bologna trials in Italy

Clinical and Immunological Outcomes of Living and Deceased Donor Transplantation Recruiting

Copeptin and Thirst: Possible Predictive Markers of Effectiveness of Bariatric Surgery? Recruiting

Comparison Between Two Hysteroscopic Biopsy Techniques in the Outpatient Setting for Sampling Hypotrophic or Atrophic Endometrium: 'Rail Biopsy' Versus 'Chip Biopsy' Recruiting

Electrochemotherapy With Carboplatinum Plus Bleomycin Versus Bleomycin Alone in Vulvar Cancer Recruiting

Appropriateness of Colonoscopy Indication: an Evaluation of the Clinical and Economic Impact. Recruiting

Other trials for the same condition

A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors Recruiting

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis Active, not recruiting

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis Active, not recruiting

A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemokine Receptor 2 Detection. From Flow Cytometry to the Development of Targeted Positron Emission Tomography Molecular Imaging. Pre-clinical Studies and First In-human Proof of Concept Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06798805 on ClinicalTrials.gov ↗ ← All trials in Italy